[Therapeutical targets for revert liver fibrosis].
Liver fibrosis is the common response to chronic liver injury, ultimately leading to cirrhosis and its complications: portal hypertension, liver failure, hepatic encephalopathy, and hepatocellular carcinoma and others. Efficient and well-tolerated antifibrotic drugs are still lacking, and current treatment of hepatic fibrosis is limited to withdrawal of the noxious agent. Efforts over the past decade have mainly focused on fibrogenic cells generating the scarring response, although promising data on inhibition of parenchymal injury or reduction of liver inflammation have also been obtained. A large number of approaches have been validated in culture studies and in animal models, and several clinical trials are underway or anticipated for a growing number of molecules. This review highlight recent advances in the molecular mechanisms of liver fibrosis and discusses mechanistically based strategies that have recently emerged.
García B
Leonel
L
Instituto de Biología Molecular en Medicina y Terapia Génica, Departamento de Biología Molecular y Genómica, CUCS, Universidad de Guadalajara, México.
Gálvez G
Javier
J
Armendáriz B
Juan
J
D000818:Animals; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D005109:Extracellular Matrix / Q000502:physiology; D016326:Extracellular Matrix Proteins / Q000502:physiology; D005347:Fibroblasts / Q000473:pathology / Q000502:physiology; D006801:Humans; D008099:Liver / Q000473:pathology* / Q000503:physiopathology; D008103:Liver Cirrhosis / Q000473:pathology* / Q000503:physiopathology / Q000628:therapy*; D010982:Platelet-Derived Growth Factor / Q000502:physiology; D016212:Transforming Growth Factor beta / Q000502:physiology
D016326:Extracellular Matrix Proteins; D010982:Platelet-Derived Growth Factor; D016212:Transforming Growth Factor beta